Molecular and Clinical Correlates with Prostate Specific Membrane Antigen (PSMA) - Targeted Radionuclide Therapy
Abstract
Prostate-specific membrane antigen (PSMA) targeted therapy is a promising new class of drugs for men with metastatic prostate cancer. PSMA is an ideal target because its expression is highly specific for prostate cancer, it is expressed by the vast majority of hormone nave and castration resistant tumors, and its cell surface expression lends opportunities for both imaging and therapy. Based on promising data led by our team and others looking at PSMA radionuclide therapy, Lu-- PSMA-617 is now in a Phase 3 trial for men with castration resistant prostate cancer. While the field is excited and encouraged by anti-tumor activity, there is still much to learn about patient and/or tumor molecular characteristics associated with response (or lack thereof) to PSMA-targeted radionuclide therapies. In this study, we are evaluating genomic biomarkers, clinical features, and PSMA molecular imaging of prospective cohorts of men treated with PSMA radionuclide therapy on our clinical trials.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2020
- Accession Number
- AD1125040
Entities
People
- Himisha Beltran
Organizations
- Dana–Farber Cancer Institute